We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
-6.01%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$148M
AUM Growth
-$13.4M
(-8.3%)
Cap. Flow
+$5.17M
Cap. Flow
% of AUM
3.49%
Top 10 Holdings %
Top 10 Hldgs %
33.04%
Holding
120
New
14
Increased
23
Reduced
48
Closed
11
Avg Time Held
3.3
years
Top 10 Avg Time Held
1.6
years
Top 20 Avg Time Held
2.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASPU
ASPEN GROUP, INC.
ASPU
|
+$3.37M |
| 2 |
UPH
UpHealth, Inc.
UPH
|
+$2.17M |
| 3 |
Augmedix, Inc. Common Stock
AUGX
|
+$1.55M |
| 4 |
Edgio, Inc. Common Stock
EGIO
|
+$1.35M |
| 5 |
Journey Medical
DERM
|
+$1.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vonage Holdings Corporation
VG
|
+$2.56M |
| 2 |
ZIXI
Zix Corporation
ZIXI
|
+$1.63M |
| 3 |
Vericel Corp
VCEL
|
+$997K |
| 4 |
CFMS
Conformis, Inc. Common Stock
CFMS
|
+$585K |
| 5 |
OptimizeRx
OPRX
|
+$557K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.58% |
| 2 | Technology | 18.56% |
| 3 | Industrials | 7.3% |
| 4 | Consumer Staples | 6.91% |
| 5 | Communication Services | 5.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Idexx Laboratories
IDXX
$42.7B
| $7.12M | 4.8% |
10,805
-300
| -3% | -$188K |
2013 Q3
33 quarters
|
|
|
2
OptimizeRx
OPRX
$165M
| $6.7M | 4.52% |
107,830
-7,350
| -6% | -$557K |
2018 Q2
14 quarters
|
|
3
Natera
NTRA
$57.8B
| $5.62M | 3.8% |
60,200
-2,200
| -4% | -$228K |
2018 Q2
14 quarters
|
|
4
NeoGenomics
NEO
$2.19B
| $5.31M | 3.58% |
155,550
-2,200
| -1% | -$86.2K |
2013 Q2
34 quarters
|
|
5
Microsoft
MSFT
$4.01T
| $5.21M | 3.52% |
15,493
| – | – |
2014 Q1
31 quarters
|
|
6
Veracyte
VCYT
$3.64B
| $5.1M | 3.44% |
123,730
-1,250
| -1% | -$55.2K |
2018 Q1
15 quarters
|
|
7
Abbott
ABT
$181B
| $3.81M | 2.57% |
27,080
-500
| -2% | -$64K |
2014 Q1
31 quarters
|
|
8
Eli Lilly
LLY
$1.14T
| $3.7M | 2.5% |
13,408
-300
| -2% | -$76.1K |
2013 Q2
34 quarters
|
|
9
Pfizer
PFE
$170B
| $3.2M | 2.16% |
54,248
-50
| -0.1% | -$2.48K |
2013 Q2
34 quarters
|
|
10
DELISTED
FlexShopper
FPAY
| $3.17M | 2.14% |
1,350,440
-128,430
| -9% | -$332K |
2018 Q3
13 quarters
|
|
11
Ooma
OOMA
$558M
| $3.08M | 2.08% |
150,425
-1,650
| -1% | -$33.6K |
2018 Q2
14 quarters
|
|
12
Inuvo
INUV
$7.63M
| $3M | 2.03% |
566,693
+83,340
| +17% | +$534K |
2018 Q2
14 quarters
|
|
13
Digi International
DGII
$2.68B
| $2.98M | 2.01% |
121,250
-5,050
| -4% | -$116K |
2020 Q1
7 quarters
|
|
|
ASPU
14
DELISTED
ASPEN GROUP, INC.
ASPU
| $2.7M | 1.82% |
1,144,375
+823,125
| +256% | +$3.37M |
2019 Q4
8 quarters
|
|
15
AtriCure
ATRC
$2.9B
| $2.67M | 1.8% |
38,350
| – | – |
2013 Q2
34 quarters
|
|
16
CareDx
CDNA
$3.46B
| $2.62M | 1.77% |
57,692
-2,750
| -5% | -$144K |
2017 Q3
17 quarters
|
|
17
Perion Network
PERI
$358M
| $2.6M | 1.75% |
108,051
-3,800
| -3% | -$92.7K |
2021 Q1
3 quarters
|
|
18
Axogen
AXGN
$2.1B
| $2.6M | 1.75% |
277,190
+3,950
| +1% | +$47.4K |
2013 Q3
33 quarters
|
|
19
DELISTED
Streamline Health Solutions
STRM
| $2.51M | 1.69% |
112,277
-14,086
| -11% | -$338K |
2018 Q2
14 quarters
|
|
|
CSLT
20
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $2.36M | 1.59% |
1,532,000
-131,000
| -8% | -$216K |
2020 Q3
5 quarters
|
|
21
DELISTED
Cantaloupe
CTLP
| $2.34M | 1.58% |
263,225
-10,500
| -4% | -$104K |
2020 Q4
4 quarters
|
|
22
Exagen
XGN
$205M
| $2.32M | 1.57% |
199,475
-6,755
| -3% | -$79.1K |
2019 Q3
9 quarters
|
|
|
XLNX
23
DELISTED
Xilinx Inc
XLNX
| $2.12M | 1.43% |
10,000
-795
| -7% | -$157K |
2021 Q1
3 quarters
|
|
24
LeMaitre Vascular
LMAT
$1.92B
| $2.11M | 1.42% |
42,000
-9,700
| -19% | -$502K |
2017 Q1
19 quarters
|
|
|
UPH
25
DELISTED
UpHealth, Inc.
UPH
| $2.1M | 1.42% |
+93,945
| New | +$2.17M |
2021 Q4
0 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Perkins Capital Management held 120 positions worth $148M, down 8.3% from $162M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Perkins Capital Management deployed $5.17M of net new capital in Q4 2021, opening 14 new positions and adding to 23 existing holdings. Its largest new stake was UpHealth, Inc.: 93,945 shares worth $2.1M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 64% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Vericel Corp, an estimated $997K trimmed.
- Perkins Capital Management's largest Q4 2021 buy was UpHealth, Inc.: 93,945 shares worth $2.1M.
- Perkins Capital Management added most to ASPEN GROUP, INC. in Q4 2021, an estimated $3.37M increase.
- Perkins Capital Management's biggest Q4 2021 reduction was Vericel Corp, cutting an estimated $997K.
- Perkins Capital Management fully exited Vonage Holdings Corporation in Q4 2021, selling an estimated $2.56M.
- Perkins Capital Management's ten largest holdings make up 33% of its $148M portfolio in Q4 2021.
- Perkins Capital Management opened 14 new positions and closed 11 in Q4 2021.
- Perkins Capital Management's portfolio value fell 8.3% quarter-over-quarter to $148M.
Based on Perkins Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.